Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Leon O. Molder Jr., Chief Executive Officer of Zenas BioPharma(NASDAQ:ZBIO), reported the open-market purchase of 60,000 shares at a weighted average price of $16.88 per share, according to the SEC Form 4 filing .
Transaction summary
| Metric |
Value |
|---|---|
| Shares traded |
60,000 |
| Transaction value |
$1.0 million |
| Post-transaction shares (direct) |
423,155 |
| Post-transaction value (direct ownership) |
~$7.16 million |
Transaction value based on SEC Form 4 weighted average purchase price ($16.88). Post-transaction value based on May 18, 2026 closing price.
Key questions
-
How does this purchase compare to Leon Moulder's historical trading activity?
This 60,000-share acquisition falls within the higher end of his transaction sizes over the past year, with several purchases in the 54,000, 60,000, 57,000, and 100,000 share range, supporting a sustained accumulation trend. -
What is the impact on overall insider ownership?
Following this transaction, Moulder controls 423,155 directly-held shares, with total beneficial ownership, including shares held indirectly via the Leon O. Moulder, Jr. Revocable Trust, exceeding 520,000 shares, or approximately 0.95% of Zenas BioPharma's outstanding shares as of the latest filing. He also holds another 1,786,039 shares indirectly through Tellus BioVentures LLC. -
What is the market context for the purchase price?
The shares were acquired at a weighted average price of $16.88, with the stock showing a 53.6% one-year total return as of the transaction date. -
Does the transaction reflect available capacity or a change in buying cadence?
The purchase leverages Moulder's increased direct ownership base, and maintains the net-buying cadence observed over the past year, with the elevated trade size matching his capacity expansion rather than signaling a deviation from established behavior.
Company overview
| Metric |
Value |
|---|---|
| Price (as of market close May 18, 2026) |
$16.91 |
| Market capitalization |
$846.87 million |
| Net income (TTM) |
($425.15 million) |
| 1-year price change |
53.6% |
* 1-year performance calculated using May 18, 2026 as the reference date.
Company snapshot
-
Zenas BioPharma develops immunology-based therapies, with a pipeline led by obexelimab targeting autoimmune and inflammatory diseases. Additional candidates include ZB002, ZB004, ZB001, and ZB005.
-
It operates a clinical-stage biopharmaceutical model focused on advancing monoclonal antibody therapies through clinical trials and regulatory approval, with revenue anticipated from future product commercialization, and potential licensing agreements.
-
The company targets healthcare providers, hospitals, and specialty clinics treating patients with autoimmune and rare immune-mediated conditions.
Zenas BioPharma is a clinical-stage biotechnology company specializing in transformative immunology therapies, with a primary focus on monoclonal antibodies for autoimmune and rare diseases.
The company leverages a robust pipeline and scientific expertise to address significant unmet medical needs in immunology. Its strategy centers on advancing late-stage product candidates and building a differentiated portfolio to establish a competitive position in the biopharmaceutical sector.
What this transaction means for investors
Zenas BioPharma CEO Leon Molder's May 18 purchase of company shares suggests he has a bullish outlook towards the stock. The buy comes after Zenas shares fell at the start of 2026 from a 52-week high of $44.60 reached in December.
Molder doesn't need to buy more shares given his sizable equity stake through both direct and indirect holdings. His accumulation of more stock points to a belief the steady advancement in the development of treatments such as obexelimab will eventually pay off.
As of June 2, a recent study regarding obexelimab revealed encouraging results of its effectiveness. Now, the race is on to achieve FDA approval before Zenas BioPharma must acquire more funding.
Zenas shares have experienced lackluster performance in 2026. This is understandable given the company's net loss in the first quarter ballooned to $81 million from $33.6 million in the prior year. Zenas exited Q1 with cash, cash equivalents and investments of $718.5 million, which can sustain operations for a time so long as costs don't continue to rise too quickly.
Should you buy stock in Zenas BioPharma right now?
Before you buy stock in Zenas BioPharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zenas BioPharma wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $417,305!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,293,148!*
Now, it's worth noting Stock Advisor's total average return is 936% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 21, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. was originally published by The Motley Fool
